Abstract
Background: Standard treatment guidelines (STGs) are a critical public health tool for promoting rational use of medicines. No studies have evaluated alignment of STGs with medicine use indicators especially in low and-middle-income countries (LMICs) with disproportionate burden of disease and irrational medicine use. Objective: To determine the level of alignment of Namibia’s STGs with WHO medicine use indicators. Methods: A descriptive policy analysis of alignment of Namibia’s STGs and WHO medicine use indicators. Thirty-two conditions/diseases prevalent and managed at primary healthcare level were included in the study of alignment of the STGs with two WHO medicine use indicators in terms of average number of medicines/condition (polypharmacy, WHO target <2) and antibiotic prescribing (WHO target <30%) after adjusting for estimated encounters per condition. Data were analyzed using (SPSSv24 software, IBM Corporation, NY) to determine frequencies, percentages and means. Key findings: Of the 32 conditions/diseases studied, 41% had three or more medicines per condition indicated in the STGs. The weighted minimum and maximum average number of medicines/condition/encounter in the STGs were 2.62 and 2.78 respectively. Antibiotics were indicated for 72% (weighted per encounter = 75%) of the 32 conditions. Conditions/diseases of the urogenital system had the highest antibiotics indicated in the STGs (100%); respiratory (80%); ENT (80%); gastrointestinal (33%) before weighting conditions for estimated patient encounters, while ENT conditions had the highest antibiotics (32%) after weighting. Conclusions: Alignment of Namibia STGs and medicine use targets is sub-optimal. The STGs have a high indication of antibiotics and polypharmacy. Misalignment is the main contributor to sub-optimal medicine use indicators with respect to average number of medicines and antibiotics. Countries should review their STGs and align with medicine use indicators to enhance rational medicine use and fight antimicrobial resistance. This article provides guidance for aligning STGs with medicine use indicators.
Original language | English |
---|---|
Pages (from-to) | 149-157 |
Number of pages | 9 |
Journal | Journal of Pharmaceutical Health Services Research |
Volume | 11 |
Issue number | 2 |
Early online date | 12 Apr 2020 |
DOIs | |
Publication status | Published - 1 Jun 2020 |
Bibliographical note
Funding Information:This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. We thank Ministry of Health and Social Services (MoHSS) for the Standard Treatment Guidelines (STGs) used in this study and for ethics clearance, and the University of Namibia for the permission granted for this study. This study did not receive any funding from any governmental or private institution.
Funding
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. We thank Ministry of Health and Social Services (MoHSS) for the Standard Treatment Guidelines (STGs) used in this study and for ethics clearance, and the University of Namibia for the permission granted for this study. This study did not receive any funding from any governmental or private institution.
Keywords
- antimicrobial resistance
- indicators
- low-and-middle income countries
- medicine use
- standard treatment guidelines (STGs)
ASJC Scopus subject areas
- Pharmacy
- Economics, Econometrics and Finance (miscellaneous)
- Pharmacology, Toxicology and Pharmaceutics (miscellaneous)